Pemetrexed-induced edema of the eyelid

Takayasu Kurata, Kenji Tamura, Isamu Okamoto, Taroh Satoh, Kazuhiko Nakagawa, Masahiro Fukuoka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Pemetrexed is a novel antimetabolite that targets multiple enzymes in the folate pathway, and has exhibited clear antitumor activities in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. Although many adverse events of pemetrexed, such as bone marrow suppression, have been reported, edema of the eyelid has been previously reported in only one case (0.2%, n = 519), according to the Pemetrexed Clinical Investigator's Brochure, April 2005 version. We experienced a patient who developed the valuable edema of the eyelid. We believe that medical oncologists should be aware of this rare adverse event, although the mechanism responsible for it is not yet known.

Original languageEnglish
Pages (from-to)241-242
Number of pages2
JournalLung Cancer
Volume54
Issue number2
DOIs
Publication statusPublished - Nov 1 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Pemetrexed-induced edema of the eyelid'. Together they form a unique fingerprint.

  • Cite this

    Kurata, T., Tamura, K., Okamoto, I., Satoh, T., Nakagawa, K., & Fukuoka, M. (2006). Pemetrexed-induced edema of the eyelid. Lung Cancer, 54(2), 241-242. https://doi.org/10.1016/j.lungcan.2006.08.002